FOXO4-DRI Canada — 10 mg Lyophilized Vials
Senolytic Research Peptide
Also known as FOXO4 D-Retro-Inverso peptide
FOXO4-DRI is a 46-residue D-retro-inverso peptide studied in research as a senolytic agent that targets the interaction between FOXO4 and p53.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
FOXO4-DRI is a 46-residue D-retro-inverso peptide studied in research as a senolytic agent that targets the interaction between FOXO4 and p53.
Experimental models examine selective removal of senescent cells in cell culture and in aged animals.
Third-party tested for purity, ID, quantity.
Coming Soon
The certificate of analysis for the 10mg lot is being finalised and will be published here as soon as the lab returns it.
FOXO4-DRI is built from D-amino acids in reversed sequence, a retro-inverso design intended to preserve side-chain topology while resisting proteolysis. Research has focused on its disruption of the FOXO4-p53 interaction, which promotes nuclear exclusion of p53 and apoptosis in senescent cells while sparing proliferating cells.
Structural work has characterized the disordered p53 transactivation domain as the binding target. Preclinical studies span expanded human chondrocytes, aged Leydig cells, keloid fibroblasts, and vascular models.
FOXO4-DRI was designed from research showing that senescent cells depend on a FOXO4-p53 interaction to avoid apoptosis. Interfering with that interaction produced selective clearance of senescent cells in early models.
Subsequent work extended the peptide across tissue-specific senescence models and characterized its molecular target in more detail, alongside reports of context-dependent adverse outcomes.
Research into FOXO4-DRI focuses on selective senescent-cell clearance through disruption of the FOXO4-p53 axis. Frameworks evaluate p53 localization, apoptosis selectivity, and tissue-level outcomes of senolysis under controlled in vitro and preclinical conditions, including studies reporting harm in specific models.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Bourgeois 2025, Huang 2021, Zhang 2020. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Huang 2021. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Huang 2021, Zhang 2020, Born 2023. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on ageing or regenerative. This heading marks where FOXO4-DRI is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 5 primary papers published between 2020 and 2025 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for FOXO4-DRI, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
FOXO4-DRI is also referred to as FOXO4, the senolytic peptide, and technically as FOXO4 D-Retro-Inverso peptide.
FOXO4-DRI is commonly described online in connection with faster healing from injury and improved recovery. In the research literature the same compound is filed under FOXO4-p53 interaction and senolysis models, retro-inverso peptide design and stability and tissue-specific senescent-cell clearance.
The 5 papers cited on this page, published between 2020 and 2025 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of FOXO4-DRI is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy FOXO4-DRI in Canada through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
FOXO4-DRI is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 46 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of FOXO4-DRI. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
PubMedSenolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
PubMedFOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
PubMedFOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
PubMedEliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
PubMedRelated
Eppix Flash Sale −30%Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$41.96$59.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$24.46$34.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$38.46$54.95CAD
Flash sale ends in
Eppix Flash Sale −30%Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$101.46$144.95CAD
Flash sale ends in
